GuruFocus
31 May 2026, 14:00 UTC · 16w ago
Verdict
Headline takes no side. We score SMMT +1.00 across one claim — strongly bullish.
+1.00strongly bullish
More positive than 99% of ticker scores this week
What the story claims
1 claim · scored −1 bearish … +1 bullish
Summit Therapeutics announced positive overall survival (OS) results from the Phase III HARMONi-6 trial in China.
So whatPositive Phase III OS data is a primary catalyst for drug approval and significant valuation increases for biotech firms.
More positive than 99% of claims this week
Which stocks this story touches
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 99% of ticker scores this week
The company announced positive overall survival results from a Phase III trial.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
8h ago
−7.6%
Price is moving against the score
$16.20 vs $17.54 close before publication (May 29) · not market-adjusted
SMMT chart →
